SYK and ZAP70 kinases in autoimmunity and lymphoid malignancies.


Journal

Cellular signalling
ISSN: 1873-3913
Titre abrégé: Cell Signal
Pays: England
ID NLM: 8904683

Informations de publication

Date de publication:
06 2022
Historique:
received: 14 03 2022
accepted: 04 04 2022
pubmed: 11 4 2022
medline: 4 5 2022
entrez: 10 4 2022
Statut: ppublish

Résumé

SYK and ZAP70 nonreceptor tyrosine kinases serve essential roles in initiating B-cell receptor (BCR) and T-cell receptor (TCR) signaling in B- and T-lymphocytes, respectively. Despite their structural and functional similarity, expression of SYK and ZAP70 is strictly separated during B- and T-lymphocyte development, the reason for which was not known. Aberrant co-expression of ZAP70 with SYK was first identified in B-cell chronic lymphocytic leukemia (CLL) and is considered a biomarker of aggressive disease and poor clinical outcomes. We recently found that aberrant ZAP70 co-expression not only functions as an oncogenic driver in CLL but also in various other B-cell malignancies, including acute lymphoblastic leukemia (B-ALL) and mantle cell lymphoma. Thereby, aberrantly expressed ZAP70 redirects SYK and BCR-downstream signaling from NFAT towards activation of the PI3K-pathway. In the sole presence of SYK, pathological BCR-signaling in autoreactive or premalignant cells induces NFAT-activation and NFAT-dependent anergy and negative selection. In contrast, negative selection of pathological B-cells is subverted when ZAP70 diverts SYK from activation of NFAT towards tonic PI3K-signaling, which promotes survival instead of cell death. We discuss here how both B-cell malignancies and autoimmune diseases frequently evolve to harness this mechanism, highlighting the importance of developmental separation of the two kinases as an essential safeguard.

Identifiants

pubmed: 35398488
pii: S0898-6568(22)00092-4
doi: 10.1016/j.cellsig.2022.110331
pii:
doi:

Substances chimiques

Receptors, Antigen, B-Cell 0
SYK protein, human EC 2.7.10.2
Syk Kinase EC 2.7.10.2
ZAP-70 Protein-Tyrosine Kinase EC 2.7.10.2
ZAP70 protein, human EC 2.7.10.2

Types de publication

Journal Article Review Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

110331

Subventions

Organisme : NCI NIH HHS
ID : R01 CA213138
Pays : United States
Organisme : NCI NIH HHS
ID : R35 CA197628
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA157644
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI164692
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA233412
Pays : United States
Organisme : Howard Hughes Medical Institute
ID : HHMI-55108547
Pays : United States

Informations de copyright

Copyright © 2022 Elsevier Inc. All rights reserved.

Auteurs

Etienne Leveille (E)

Center of Molecular and Cellular Oncology, Yale University, New Haven, CT 06511, USA; Department of Internal Medicine, Section of Hematology, Yale School of Medicine, New Haven, CT 06510, USA.

Lai N Chan (LN)

Center of Molecular and Cellular Oncology, Yale University, New Haven, CT 06511, USA; Department of Internal Medicine, Section of Hematology, Yale School of Medicine, New Haven, CT 06510, USA.

Abu-Sayeef Mirza (AS)

Center of Molecular and Cellular Oncology, Yale University, New Haven, CT 06511, USA; Department of Internal Medicine, Section of Hematology, Yale School of Medicine, New Haven, CT 06510, USA.

Kohei Kume (K)

Center of Molecular and Cellular Oncology, Yale University, New Haven, CT 06511, USA.

Markus Müschen (M)

Center of Molecular and Cellular Oncology, Yale University, New Haven, CT 06511, USA; Department of Immunobiology, Yale University, CT 06520, USA. Electronic address: markus.muschen@yale.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH